ABOUT
Our Members
Board of Directors
Staff
Our Support
Contact Us
Issue Areas
COVID-19
Health Equity, Diversity, & Inclusion
Reducing Health Costs
Health Care Reform
Value
Real-World Evidence
Patient Engagement
FDA Regulations
Resources
Member Resources
Fair-Market Value Calculator
Patient Experience Mapping
Meetings & Events
Newsroom
Letters & Comments
Job Bank
Education
Real-World Evidence Classroom
Value Classroom
Patient-Focused Medical Product Development Series
Clinical Outcome Assessment Series
Health Literacy Series
Health Care Quality
Webinars
Blog
Membership
Our Members
Standards of Excellence
Join Us
Accessibility Tools
Toggle navigation
letters & comments
Statement for the Record: FDA User Fee Reauthorization: Ensuring Safe and Effective Drugs and Biologics
02/03/2022
Read More
NHC Comments on HHS Notice of Benefit and Payment Parameters for 2023
01/27/2022
Read More
Letter of Support for Dr. Robert Califf FDA Commissioner Nominee
12/13/2021
Read More
NHC Comments on FDA-2020-D-2316 for Benefit-Risk Assessment for New Drug and Biological Products; Draft Guidance for Industry
11/29/2021
Read More
NHC RWE, EHR and Medical Claims Comments
11/29/2021
Read More
NHC Comments on PDUFA Reauthorization Performance Goals and Procedures FY 2023-2027
10/29/2021
Read More
CMS Physician Fee Schedule Proposed Rule
09/13/2021
Read More
Recommendations to Congress for Reconciliation Legislation
09/08/2021
Read More
Patient-Centered Outcomes Research Institute (PCORI) National Health Priorities
08/27/2021
Read More
« Previous
1
2
3
4
5
6
7
8
9
10
11
12
13
Next »
